|1.||Gretskaia, N M: 2 articles (01/2012 - 07/2008)|
|2.||Kurdiumov, I N: 2 articles (01/2012 - 07/2008)|
|3.||Gan'shina, T S: 2 articles (01/2012 - 07/2008)|
|4.||Bezuglov, V V: 2 articles (01/2012 - 07/2008)|
|5.||Mirzoian, R S: 2 articles (01/2012 - 07/2008)|
|6.||Garg, Puja: 1 article (07/2015)|
|7.||Prokai-Tatrai, Katalin: 1 article (07/2015)|
|8.||Koulen, Peter: 1 article (07/2015)|
|9.||Conrad, Cheryl D: 1 article (07/2015)|
|10.||Talboom, Joshua S: 1 article (07/2015)|
|1.||Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
01/01/2000 - "The cognitive deficits caused by EC lesion and middle cerebral artery occlusion were improved significantly by repeated administrations of DHED (6.25 mg/kg i.p.) after EC lesion or ischemic insult once a day for 7 days in the passive avoidance test. "
01/01/2000 - "In addition, we examined the effects of DHED on the memory impairment and the histological changes of the brain after unilateral electrolytic lesion of the entorhinal cortex (EC) and middle cerebral artery occlusion in rats. "
|2.||Alzheimer Disease (Alzheimer's Disease)
01/01/2000 - "These results suggest that DHED might be an effective drug for not only the Alzheimer's disease type, but also the vascular type of dementia."
10/01/1996 - "These results indicate that DHED has novel anti-cholinesterase and antiamnesic activities and might have therapeutic potential in various disorders including Alzheimer's disease."
10/01/1996 - "The antiamnesic effect of DHED was more potent than that of tacrine which is the only drug for Alzheimer's disease approved by FDA. "
11/01/2007 - "This study was to investigate the effect of dehydroevodiamine (DHED) on Alzheimer's disease (AD)-like tau hyperphosphorylation induced by calyculin A (CA), an inhibitor of protein phosphatase (PP)-2A and PP-1, and the involvement of PP-2A in metabolically competent rat brain slices. "
|3.||Memory Disorders (Memory Loss)
06/01/2007 - "Our study gave the first in vivo evidence that DHED could suppress the overactivation of GSK-3 and improve tau hyperphosphorylation and spatial memory deficit of the rats, suggesting that this chemical may be served as a candidate for arresting AD-like pathological and behavioral alterations."
|4.||Transient Ischemic Attack
07/01/2008 - "The GABA - DHED conjugate was shown to significantly enhance the cerebral circulation in rats with a model of global transient cerebral ischemia, as compared to the intact animals. "
01/01/2012 - "A GABA conjugate with docosahexaenoyl dophamine (DHED) enhanced local cerebral blood flow in rats under conditions of global transient cerebral ischemia, experimental myocardial infarction, and combined vascular pathology of brain and heart. "
|1.||Glycogen Synthase Kinase 3
|4.||gamma-Aminobutyric Acid (GABA)
|9.||P-30 composite resin (P 30)